Clinical Trial Update: Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb) [Phase 2]

View source ↗

Summary

Phase IIb dose-ranging study in COPD completed; results posted in 2018 for formoterol in ACHIEVE Duaklir USA program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol (formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease - COPD | Phase 2 | Status: COMPLETED | Results posted: 2018-02-07